Arcturus Therapeutics Holdings (ARCT) Cash from Investing Activities (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) reported Cash from Investing Activities of $34000.0 for Q1 2026, up 124.82% on a YoY basis from $15123.4 in Q1 2025, and down 61.36% quarter-over-quarter from $88000.0 in Q4 2025.
Arcturus Therapeutics Holdings (ARCT) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings has reported Cash from Investing Activities for 9 years, with the latest figure at $34000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 124.82% year-over-year to $34000.0; the trailing twelve-month figure through Mar 2026 stood at -$59000.0 (up 89.17% YoY), and the FY2025 full-year result was -$230000.0, up 64.51% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $34000.0, down from $88000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $378000.0 in Q2 2022, with the low at -$3.8 million in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$764733.3 across 5 years, with a median of -$328000.0 in 2024.
- The largest YoY upside for Cash from Investing Activities was 193.56% in 2022 against a maximum downside of 1688.98% in 2022.
- Arcturus Therapeutics Holdings' Cash from Investing Activities stood at -$3.8 million in 2022, then jumped by 77.02% to -$875000.0 in 2023, then soared by 90.86% to -$80000.0 in 2024, then soared by 210.0% to $88000.0 in 2025, then tumbled by 61.36% to $34000.0 in 2026.
- The last three Cash from Investing Activities figures came in at $34000.0 (Q1 2026), $88000.0 (Q4 2025), and -$181000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Arcturus Therapeutics Holdings | 217.14 Mn | 5.76 Mn | - | 34,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34,000.00 |
| Mar 31, 2026 | 34,000.00 |
| Dec 31, 2025 | 88,000.00 |
| Dec 31, 2025 | 88,000.00 |
| Sep 30, 2025 | -181,000.00 |
| Sep 30, 2025 | -181,000.00 |
| Mar 31, 2025 | -137,000.00 |
| Mar 31, 2025 | -137,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Jun 30, 2024 | -328,000.00 |
| Jun 30, 2024 | -328,000.00 |
| Mar 31, 2024 | -240,000.00 |
| Mar 31, 2024 | -240,000.00 |
| Dec 31, 2023 | -875,000.00 |
| Dec 31, 2023 | -875,000.00 |
| Sep 30, 2023 | -981,000.00 |
| Sep 30, 2023 | -981,000.00 |
| Jun 30, 2023 | -354,000.00 |
| Jun 30, 2023 | -354,000.00 |